Staging preview: health content pending qualified review
D2C Peptides

Research goal

Peptides and healing and recovery

Most healing evidence for these peptides comes from rats, not people: of 36 BPC-157 studies in one review, 35 were preclinical.73 Human data are thin: the three BPC-157 studies in people had 30 participants and no control group.1 One of the few controlled positive results is a 1994 trial of a copper peptide (GHK-Cu) gel on diabetic foot ulcers.2 This page maps what published sources report on each peptide searched with healing and recovery, and makes no promise.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

Tissue repair peptides

BPC-157

BPC-157 is a 15-amino-acid peptide based on a protein found in human gastric juice.3 In rats it improved healing of cut Achilles tendons, quadriceps muscle and knee ligaments.161710 In rat gut studies summarized by FDA, fistulas in treated rats were about 40% smaller from day 3.18 A 2026 systematic review found only three human studies, 30 people in all with no control group, and rated the certainty of evidence very low.1 See What is BPC-157? and BPC-157 for sale.

TB-500

Evidence for TB-500 itself comes from animal and cell studies, with mixed results.1920 In a 2026 rat study, repaired Achilles tendons treated with TB-500 had better tissue scores and a strength advantage at 4 weeks.19 In a 2024 cell study, TB-500 did not speed scratch-wound closure, though one of its breakdown products did.520 Its parent protein, full-length thymosin beta-4, increased skin regrowth over rat wounds by 42% at 4 days.21 FDA states the two are not the same substance.5 FDA's May 2026 review found no article in which TB-500 was given to people, and a lack of evidence to evaluate it for wound healing.5 See What is TB-500? and TB-500 for sale.

Wolverine Stack

The Wolverine Stack pairs BPC-157 with TB-500. Its evidence is one rat Achilles tendon study, in which combining the two added no benefit over either alone.22 The human reports are small and uncontrolled. In a knee-pain chart review, 3 of 4 patients given BPC-157 with full-length thymosin beta-4 (not TB-500) reported improvement.23 Three dental nerve-injury patients received BPC-157 and TB-500 along with ARA-290, a steroid and a local anesthetic, and the authors note that causality cannot be established.24 FDA's 2026 review describes a person who had significant adverse reactions after a BPC-157 and TB-500 injection product labeled for research purposes only.25 See What is Wolverine Stack (BPC-157 + TB-500)? and Wolverine Stack (BPC-157 + TB-500) for sale.

GHK-Cu

GHK-Cu has one of the few controlled human healing results on this page.2 In a 1994 randomized, placebo-controlled trial in diabetic foot ulcers, a topical GHK-Cu gel with standard care closed a median 98.5% of ulcer area, against 60.8% with the inactive gel.2 In ulcers treated right after cleaning, infections fell to 7% from 34%.26 A phase 2 trial of a 0.1% gel on standardized skin wounds in healthy adults is registered, with no results as of October 2026.27 In rats, knee injections improved ligament graft healing only while treatment continued.28 A 2026 review found no clinical data supporting GHK-Cu for musculoskeletal conditions.29 See What is GHK-Cu? and GHK-Cu for sale.

Glow and KLOW blends

Glow combines GHK-Cu, BPC-157 and TB-500, and KLOW adds KPV to the same three.3031 A PubMed search finds no study of either blend.32 A 2026 scoping review concluded that the claimed musculoskeletal recovery benefits of these peptides remain unsubstantiated by human trials.33 Read What is Glow Peptide Stack? and What is KLOW Peptide Blend?, or see Glow Peptide Stack for sale and KLOW Peptide Blend for sale.

KPV

KPV's healing evidence is from animals.11 Given by mouth, it reduced colitis in mice,12 and it sped recovery in other mouse colitis models.13 A KPV hydrogel helped rats with chemotherapy mouth sores regain food intake and weight.14 FDA found no human data and concluded there is a lack of evidence to evaluate KPV for wound healing or inflammatory conditions.11 See What is KPV? and KPV for sale.

Thymosin Alpha-1

Thymosin alpha-1 is an immune peptide, not a tissue-repair peptide.7 None of the 12 uses FDA reviewed in 2024 involved wound or injury healing, and FDA found a lack of evidence for all of them.8 Its advisory committee voted 17 to 4 against it.34 See What is Thymosin Alpha-1? and Thymosin Alpha-1 for sale.

Growth hormone axis peptides

HGH

In adults with large burns, two trials pooled by Cochrane found that growth hormone healed burn wounds about 9 days faster than placebo.35 The risk of high blood sugar was about 2.4 times higher.36 In prolonged critical illness, high-dose growth hormone roughly doubled deaths (39% against 20%, and 44% against 18%).37 The label contraindicates it in acute critical illness after surgery or trauma.38 See What is HGH? and HGH for sale.

GHRP-2

In a rat rotator cuff tear model, GHRP-2 improved tendon-to-bone healing on tissue, bone density and strength measures.39 In 33 men with prolonged critical illness, GHRP-2 alone restored growth hormone and IGF-1 but did not reduce protein breakdown, which needed added TRH.40 See What is GHRP-2? and GHRP-2 for sale.

GHRP-6

GHRP-6's protective findings come from animals, such as 78% less heart muscle death in pigs after a blocked artery and less liver and stomach damage in other models.4142 A 2026 review notes that these heart findings lack confirmation from human trials.43 See What is GHRP-6? and GHRP-6 for sale.

Ipamorelin

Ipamorelin sped gut recovery and stomach emptying in rats after abdominal surgery.4445 In a phase 2 trial of 114 bowel-surgery patients, it did not significantly shorten the time to a first tolerated meal (25.3 against 32.6 hours).46 See What is Ipamorelin? and Ipamorelin for sale.

CJC-1295

FDA's 2024 review lists no study in which any form of CJC-1295 was given to people with a disease or condition.47 Claims of cellular repair and post-injury recovery come from websites.48 A 2026 scoping review that included CJC-1295 found claimed musculoskeletal recovery benefits unsubstantiated by human trials.33 Read What is CJC-1295 with DAC?, What is CJC-1295 No DAC? and What is CJC-1295 + Ipamorelin?.

IGF-1 LR3

In steroid-treated rats, IGF-1 and especially its variants were anabolic, with LR3 about 2.5 times as potent as IGF-1, and they raised gut weight by up to 45%.4950 No human study of LR3 is registered.51 See What is IGF-1? and IGF-1 for sale.

MGF

In animals, MGF peptides sped healing of bone defects in rabbits and of injured Achilles tendons in rats.5253 In mice with bruised muscle, MGF reduced scarring without improving muscle fiber regrowth.54 A 2026 review lists no peer-reviewed human studies of MGF.43 See What is MGF? and MGF for sale.

Tesamorelin

A phase 2 trial of tesamorelin to improve function after peripheral nerve injury has been listed as recruiting since 2018.55 A 2026 sports medicine review calls growth hormone axis peptides, tesamorelin included, investigational in that field.56 See What is Tesamorelin? and Tesamorelin for sale.

AOD-9604

In a rabbit model of knee osteoarthritis, AOD-9604 injected into the joint enhanced cartilage regeneration.57 FDA did not evaluate osteoarthritis or osteoporosis uses for lack of information.58 It noted signals of negative effects on bone health in rats given the peptide by mouth for 13 weeks.59 See What is AOD-9604? and AOD-9604 for sale.

Nerve, organ and cell research

  • SS-31. In rats it protected mitochondria during kidney ischemia.60 In people, a heart attack trial found no reduction in infarct size, while a 14-patient kidney artery stenting pilot reported better kidney blood flow and function.6162 Read What is SS-31?.
  • ARA-290. In 28-day trials in people with sarcoidosis-related nerve loss, it increased corneal nerve fiber area and regenerating skin nerve fibers, but pain improved about as much on placebo.6364 Read What is ARA-290?.
  • Semax. Its recovery research concerns the nervous system: better function after spinal cord injury in mice, and faster recovery in a Russian stroke rehabilitation study.6566 Read What is Semax?.
  • Cortagen. In one rat study it raised the regrowth rate of a repaired sciatic nerve by 27% and its conduction velocity by 40%.67 Read What is Cortagen?.
  • Cartalax. In cell studies it switched on cartilage-forming genes in aging stem cells and normalized aging markers in cartilage cells.6869 Read What is Cartalax?.
  • Epithalon. In human retinal cells damaged by high glucose it improved scratch-wound closure, and a 2026 review found direct evidence in musculoskeletal disease models lacking.70 Read What is Epithalon?.
  • Vilon. In rats with liver cirrhosis it had only a weak effect on liver regeneration.71 Read What is Vilon?.
  • DSIP. No study of DSIP for injury healing was found, and FDA evaluated it only for insomnia, narcolepsy and opioid withdrawal.72 Read What is DSIP?.

How to read this research

Healing claims for peptides lean on rats: a 2025 systematic review of BPC-157 in orthopaedic sports medicine counted 36 studies, 35 of them preclinical, and found no clinical safety data.73 Read each result for species, injury model and route: a peptide injected into a rat's abdomen after a surgical tendon cut is a long way from an athlete's strain.22 Ask whether there was a control group; the BPC-157 human studies had none.1 Check the molecule, too, since thymosin beta-4 results do not transfer automatically to TB-500.5 Advisory votes are not approvals. In July 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend adding BPC-157, KPV and TB-500 to the substances pharmacies may compound, against FDA staff advice.7475 FDA must still decide whether to accept these nonbinding recommendations.75 Each profile page gives the compound's side effects and regulatory status. The muscle growth page covers muscle claims for the same peptides, and the safety basics guide explains how to weigh compounds that are not approved.

Other research goals

Frequently asked questions

What are the key differences between TB500 and BPC-157?

They are different molecules. BPC-157 is a 15-amino-acid peptide based on a protein found in human gastric juice,3 while TB-500 is a short fragment of thymosin beta-4 (LKKTETQ).4 BPC-157 has many rat studies and three small human studies.1 TB-500 has a few animal and cell studies.1920 FDA's May 2026 review found no article in which it was given to people, and a later 2026 report describes 3 dental patients who received it with other drugs.524 WADA bans both at all times, BPC-157 as a non-approved substance and TB-500 as a growth factor.6

Is thymosin alpha 1 the same as TB500?

No. Thymosin alpha-1 is a 28-amino-acid immune peptide isolated from calf thymus in 1977,7 while TB-500 is a seven-amino-acid fragment of a different protein, thymosin beta-4.4 Thymosin alpha-1 was studied for infections, cancers and vaccine response, and FDA found a lack of evidence for the 12 uses it reviewed.8 TB-500 is promoted for tissue repair, but FDA found no article in which it was given to people.5

Can BPC-157 heal joints?

That has not been shown in a controlled human trial.9 In rats, BPC-157 improved healing of cut knee ligaments.10 The main human data are a retrospective review of knee injections in 16 patients with no control group.1 A 2026 systematic review rated the certainty of all the human evidence very low.1 USADA notes that no human clinical trial has established BPC-157's efficacy for any diagnosis or treatment.9

Does KPV help with gut health?

Only animal data exist: FDA's 2026 review found no clinical studies or human exposure data for KPV by any route.11 Given by mouth, KPV reduced colitis in mice,12 and in other mouse colitis models it led to earlier recovery and weight regain.13 A KPV gel also helped rats recover from chemotherapy mouth sores.14 In July 2026 an FDA advisory committee voted 8 to 6 to recommend it for pharmacy compounding, a recommendation that does not bind FDA.1575

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety (Poolton JT, Minett J, Kazmi A; PMID 42885452). Acta Orthopaedica Belgica (PubMed abstract via NCBI E-utilities), 2026.
  2. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (PubMed 17147644), closure results. Wound Repair and Regeneration, 1994.
  3. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang CH, et al.; PMID 21030672). Journal of Applied Physiology (PubMed abstract via NCBI E-utilities), 2011.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026.
  5. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). U.S. Food and Drug Administration, 2026.
  6. World Anti-Doping Code International Standard: Prohibited List 2026 (official English text, copy hosted by the Czech National Sports Agency). World Anti-Doping Agency (WADA), 2025.
  7. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide (Goldstein AL et al.; PMID 265536, PMCID PMC392366). Proceedings of the National Academy of Sciences of the USA (abstract via PubMed, NCBI E-utilities), 1977.
  8. Thymosin Alpha-1 (Ta1) Related Bulk Drug Substances (FDA presentation slides, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024). U.S. Food and Drug Administration, 2024.
  9. BPC-157: Experimental Peptide Creates Risk for Athletes (undated page; references the July 2026 FDA advisory meeting). U.S. Anti-Doping Agency (USADA), 2026.
  10. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat (Cerovecki T, et al.; PMID 20225319). Journal of Orthopaedic Research (PubMed abstract via NCBI E-utilities), 2010.
  11. FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA briefing document for the July 23-24, 2026 PCAC meeting (memo dated 5/12/2026). U.S. Food and Drug Administration, 2026.
  12. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso G et al.) [PMID 18061177]. Gastroenterology (abstract via NLM PubMed E-utilities), 2008.
  13. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Kannengiesser K et al.) [PMID 18092346]. Inflammatory Bowel Diseases (abstract via NLM PubMed E-utilities), 2008.
  14. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis (Shao W et al.) [PMID 34846053]. Biomaterials Science (abstract via NLM PubMed E-utilities), 2021.
  15. FDA advisory committee backs two controversial peptides (23 July 2026). Regulatory Affairs Professionals Society (RAPS), 2026.
  16. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth (Staresinic M, et al.; PMID 14554208). Journal of Orthopaedic Research (PubMed abstract via NCBI E-utilities), 2003.
  17. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157 (Staresinic M, et al.; PMID 16609979). Journal of Orthopaedic Research (PubMed abstract via NCBI E-utilities), 2006.
  18. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), PCAC Meeting July 23-24, 2026. U.S. Food and Drug Administration, 2026.
  19. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer et al., PMID 42542926). Joint Diseases and Related Surgery, 2026.
  20. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro (Rahaman et al., PMID 38382158). Journal of Chromatography B, 2024.
  21. Thymosin beta4 accelerates wound healing (Malinda KM et al.). Journal of Investigative Dermatology, 1999.
  22. Same source as 19: A histopathological and biomechanical study (Biçer O, Adanir O, et al.; PMID 42542926).
  23. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee E, Padgett B; PMID 34324435). Alternative Therapies in Health and Medicine, 2021.
  24. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases (Froum S, et al.; PMID 42876687). Frontiers in Oral Health, 2026.
  25. Same source as 18: Pharmacy Compounding Advisory Committee, July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), dated 5/11/2026.
  26. Same source as 2: infection results.
  27. ClinicalTrials.gov NCT07437586: Topical GHK-Cu Gel for Acute Skin Wound Healing (official title). ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  28. Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction (PubMed 25731775), conclusion. Journal of Orthopaedic Research, 2015.
  29. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PubMed 41476424), results. American Journal of Sports Medicine, 2026.
  30. Supplier product specification.
  31. Supplier product specification.
  32. NCBI E-utilities PubMed search: 'GLOW' or 'KLOW' with peptide and GHK, BPC, TB-500 or thymosin (title/abstract). NCBI, U.S. National Library of Medicine, 2026.
  33. Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari K et al.). American Journal of Sports Medicine, 2026.
  34. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. U.S. Food and Drug Administration, 2025.
  35. Breederveld RS, Tuinebreijer WE 2014 (PMID 25222766): burn wound healing in adults. Cochrane Database of Systematic Reviews, via PubMed (NCBI E-utilities), 2014.
  36. Same source as 35: hyperglycaemia.
  37. Takala J et al. 1999 (PMID 10477776): mortality. New England Journal of Medicine, via PubMed (NCBI E-utilities), 1999.
  38. GENOTROPIN prescribing information: 4 Contraindications (acute critical illness). U.S. Food and Drug Administration (Drugs@FDA label, Pfizer), 2025.
  39. Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model (Li Y et al.). Arthroscopy (PubMed record via NCBI E-utilities), 2025.
  40. The combined administration of GHRP-2, TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone (Van den Berghe G et al.). Clinical Endocrinology (PubMed record via NCBI E-utilities), 2002.
  41. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction (Berlanga J et al.; PMID 16989643). Clinical Science (abstract via NCBI PubMed E-utilities), 2007.
  42. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects (full text, PMC5392015). Clinical Medicine Insights: Cardiology (full text via Europe PMC, EMBL-EBI), 2017.
  43. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski A et al.; full text). Frontiers in Endocrinology, 2026.
  44. Venkova K, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus (PubMed abstract, PMID 19289567). Journal of Pharmacology and Experimental Therapeutics, 2009.
  45. Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus (PubMed abstract, PMID 27186127). Journal of Experimental Pharmacology, 2012.
  46. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (PubMed abstract, PMID 25331030). International Journal of Colorectal Disease, 2014.
  47. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 24, compounding history and human use). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  48. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 25, claims made on websites). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  49. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats (Tomas et al.), abstract: relative potency. Biochemical Journal (PubMed PMID 1371669), 1992.
  50. Same source as 49: Tomas et al. 1992 (Biochem J), abstract: gut weight.
  51. ClinicalTrials.gov API query: all fields for 'IGF-1 LR3', 'Long R3 IGF-I', 'LR3 IGF-1', 'Long R3 IGF-1' or 'LongR3' (run October 24, 2026). ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  52. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits (Deng M, et al.). International Orthopaedics, 2011.
  53. Mechano-growth factor E peptide promotes healing of rat injured tendon (Zhang B, et al.). Biotechnology Letters, 2016.
  54. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection (Liu X, et al.). Frontiers in Physiology, 2019.
  55. ClinicalTrials.gov: NCT03150511, Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury. ClinicalTrials.gov, U.S. National Library of Medicine, 2026.
  56. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications (Villegas Meza AD et al.). JBJS Rev (PubMed abstract via NCBI E-utilities), 2026.
  57. Kwon and Park 2015, PubMed abstract: conclusion. Annals of Clinical and Laboratory Science 45(4):426-32, 2015.
  58. FDA Briefing Document, December 4, 2024: uses not evaluated. U.S. Food and Drug Administration, 2024.
  59. Same source as 58: bone health signal in rats.
  60. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology (PubMed abstract, PMID 23813215), 2013.
  61. EMBRACE STEMI study (primary result). European Heart Journal (PubMed abstract, PMID 26586786), 2016.
  62. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circulation: Cardiovascular Interventions (PubMed abstract, PMID 28916603), 2017.
  63. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Dahan A, et al.; full text). Molecular Medicine, via PubMed Central, 2013.
  64. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain (Culver DA, et al.; PubMed abstract, PMID 28475703). Investigative Ophthalmology & Visual Science, via NCBI PubMed (E-utilities), 2017.
  65. Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice [PMID 40692165]. British Journal of Pharmacology (abstract via NLM PubMed E-utilities), 2025.
  66. The efficacy of semax in the treatment of patients at different stages of ischemic stroke [PMID 29798983] (results). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (abstract via NLM PubMed E-utilities), 2018.
  67. Effect of tetrapeptide cortagen on regeneration of sciatic nerve. Bulletin of Experimental Biology and Medicine, 2000.
  68. Myakisheva SN, et al. The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging. Adv Gerontol. 2023;36(3):383-390 (in Russian). Advances in Gerontology; record via PubMed (NLM), 2023.
  69. Myakisheva SN, et al. Peptides prevent the forming of secretory phenotype of chondrocytes associated with the aging. Adv Gerontol. 2023;36(2):234-238 (in Russian). Advances in Gerontology; record via PubMed (NLM), 2023.
  70. Jain A, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci. 2026;27(19):8922 (PMC13664938). International Journal of Molecular Sciences (MDPI), 2026.
  71. Effect of 'vilon' on cirrhotically changed rat liver. Tsitologiia, 2000.
  72. FDA Briefing Document, PCAC July 23-24, 2026: Emideltide-Related Bulk Drug Substances (dated 5/11/2026). U.S. Food and Drug Administration, 2026.
  73. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi N et al.). HSS Journal, 2025.
  74. Same source as 15.
  75. FDA panel backs 6 peptides for compounding (news, July 31, 2026). AJMC (The American Journal of Managed Care), 2026.